NTpharma LLCNTpharma LLC

Production of vaccines and biopharmaceuticals based on pseudoadenoviral nanoparticles and special nanostructuresProduction of vaccines and biopharmaceuticals based on pseudoadenoviral nanoparticles and special nanostructures


Nanovaccines and biopharmaceuticals in pseudoadenoviral nanoparticles and self-assembling nanostruct

Nanovaccines and nanopharmaceuticals.

Total budget (including non-material assects): 1,547 million rubles
RUSNANO financing: 1,300 million rubles

Project participants: RUSNANO, Prom-Bi (technology developer), private co-investor.

Project stages

Project initiation Production start up Market share
Sales volume
1,395 million
rubles annually
Design capacity
2010 2013 2014 2015 2017


Flu nanovaccineThe project will bring two nanovaccines and four pharmaceuticals to the market. The vaccines will be used for protection against avian and human influenza viruses.

The technology to be used in manufacturing the nanovaccines will reduce the time for obtaining the drugs in industrial scale from 60 days to 28 days, something vital for development of vaccines against pandemic strains of the influenza virus. The pharmceuticals will be used to treat various types of ischemia, urogenital infections, and toxicosis and to activate the immune system.

All drugs and vaccines are exclusive products of NTpharma.

Recombinant Adenoviral Nanoparticles and Nanocontainer

Structure of nanoparticles as carriers of human and avian influenza virus genes, human lactoferrin virus gene, endothelial growth factor genes, and human angiogenin.

Recombinant Adenoviral Nanoparticles and Nanocontainer

Competitive advantages:

  • Production cycle, half as long as the conventional one
  • No viruses multiplying in the cells


Areas of application: medicine.



  • Flu vaccines produced without antigens
  • Immune activators carried to the organism in nanocontainers


Social impact by 2015: independence from import of vaccines.


Production locations: Pereslavl-Zalessky, Yaroslavl Oblast. Creation of 150 new jobs.


Close window


Close window